

OncoTherapy Science, Inc.

December 22, 2021

Announcement of the press release from QST regarding the publication of  
<sup>225</sup>Ac-labeled OTSA101

OncoTherapy Science, Inc. (President & CEO: Jae-Hyun Park; hereinafter, “OncoTherapy”) announces that National Institutes for Quantum Science and Technology (hereinafter; QST) has issued a press release announcing a publication of the article regarding anti-FZD10 antibody that OncoTherapy possesses its intellectual property rights.

In this collaborative research with QST, anti-FZD10 antibody labeled with  $\alpha$ -emitter radioisotope <sup>225</sup>Ac (<sup>225</sup>Ac-labeled OTSA101) showed strong anti-tumor effect at lower radiation dose in xenograft mice model of human synovial sarcoma.

Please see the details on QST website (<https://www.qst.go.jp/site/press/20211222.html>).

The paper has been published in Cancer Science on December 22, 2021.

<https://onlinelibrary.wiley.com/doi/10.1111/cas.15235>